Attached files

file filename
EX-32.1 - EXHIBIT 32.1 - Adhera Therapeutics, Inc.t1401584_ex32-1.htm
EX-31.1 - EXHIBIT 31.1 - Adhera Therapeutics, Inc.t1401584_ex31-1.htm
EXCEL - IDEA: XBRL DOCUMENT - Adhera Therapeutics, Inc.Financial_Report.xls

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 10-Q

 

 

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarter Ended March 31, 2014

 

Commission File Number 000-13789

 

 

MARINA BIOTECH, INC.

(Exact name of registrant as specified in its charter)

 

 

 

   
Delaware 11-2658569

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

   
P.O. Box 1559, Bothell, WA 98041
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (425) 892-4322

 

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ¨ No þ

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨ No þ

 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check One):

 

Large accelerated filer ¨ Accelerated filer ¨
       
Non-accelerated filer ¨ (Do not check if a smaller reporting company) Smaller reporting company þ

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

 

Date   Class   Shares Outstanding
August 7, 2014   Common stock — $0.006 par value   25,633,061

 

 

 

 
 

  

MARINA BIOTECH, INC. AND SUBSIDIARIES

TABLE OF CONTENTS

 

PART I — FINANCIAL INFORMATION  
   
ITEM 1 — FINANCIAL STATEMENTS (unaudited)  3
Condensed Consolidated Balance Sheets as of December 31, 2013 and March 31, 2014 3
Condensed Consolidated Statements of Operations for the three months ended March 31, 2013 and 2014 4
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2013 and 2014 5
Notes to Condensed Consolidated Financial Statements 6
ITEM 2 — MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS  13
ITEM 3 — QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 16
ITEM 4 — CONTROLS AND PROCEDURES 16
   
PART II — OTHER INFORMATION  
ITEM 2 — UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 17
ITEM 6 — EXHIBITS 17
SIGNATURES 18
EXHIBIT INDEX 19

 

Items 1, 1A, 3, 4 and 5 of PART II have not been included as they are not applicable.

 

2

 

PART I — FINANCIAL INFORMATION

 

ITEM 1 — FINANCIAL STATEMENTS

 

MARINA BIOTECH, INC. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

   December 31,   March 31, 
(In thousands, except share data)  2013   2014 
ASSETS          
Current assets:          
Cash  $909   $5,520 
Accounts receivable   5    - 
Prepaid expenses and other current assets   128    137 
Total current assets   1,042    5,657 
Intangible assets   6,700    6,700 
Total assets  $7,742   $12,357 
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
Current liabilities:          
Accounts payable  $1,614   $1,590 
Accrued payroll and employee benefits   1,505    280 
Accrued interest   147    - 
Other accrued liabilities   1,315    816 
Accrued restructuring   12    12 
Notes payable   1,615    - 
Other debt   8    5 
Total current liabilities   6,216    2,703 
Fair value liability for price adjustable warrants   5,226    14,606 
Fair value of stock to be issued to settle liabilities   1,019    - 
Deferred tax liabilities   2,345    2,345 
Total liabilities   14,806    19,654 
Commitments and contingencies          
Stockholders’ deficit:          
Series C convertible preferred stock, $.01 par value; none and 1,200 shares authorized, issued and outstanding at December 31, 2013 and March 31, 2014, respectively (preference in liquidation of $6,000 at March 31, 2014)   -    - 
Common stock, $0.006 par value; 180,000,000 shares authorized, 16,937,661 and 25,603,309 shares issued and outstanding at December 31, 2013 and March 31, 2014, respectively   102    155 
Additional paid-in capital   324,145    332,937 
Accumulated deficit   (331,311)   (340,389)
Total stockholders’ deficit   (7,064)   (7,297)
Total liabilities and stockholders’ deficit  $7,742   $12,357 

 

See accompanying notes to the condensed consolidated financial statements.

 

3

 

MARINA BIOTECH, INC. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

   Three Months Ended March 31, 
(In thousands, except per share data)  2013   2014 
License and other revenue  $-   $- 
Operating expenses:          
Research and development   116    46 
General and administrative   210    517 
Total operating expenses   326    563 
Loss from operations   (326)   (563)
Other income (expense):          
Interest and other expense   (59)   (1,007)
Change in fair value liability for price adjustable warrants   2,042    (5,314)
Change in fair value of stock reserved for issuance to settle liabilities   377    (2,455)
Change in fair value of embedded features in notes and amendments to notes   272    - 
Gain (loss) on debt extinguishment   (930)   4 
Gain on settled liabilities   -    257 
Total other income (expense), net   1,702    (8,515)
Net income (loss)   1,376    (9,078)
Deemed dividend related to discount on beneficial conversion feature in Series C convertible preferred shares   -    (6,000)
Net income (loss) applicable to common stockholders  $1,376   $(15,078)
           
Net income (loss) per common share          
Basic  $0.08   $(0.70)
Diluted  $0.06   $(0.70)
           
Shares used in computing net income (loss) per share          
Basic   16,938    21,447 
Diluted   24,286    21,447 

 

See accompanying notes to the condensed consolidated financial statements.

 

4

 

MARINA BIOTECH, INC. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   Three Months Ended March 31, 
(In thousands)  2013   2014 
Operating activities:          
Net income (loss)  $1,376   $(9,078)
Adjustments to reconcile net income (loss) to net cash used in operating activities:          
Non-cash (gain) loss on debt extinguishment   930    (4)
Non-cash interest expense   59    1,007 
Compensation related to stock options, restricted stock and employee stock purchase plan   29    59 
Non-cash gain on settlement of liabilities   -    (257)
Changes in fair market value of liabilities          
Price adjustable warrants   (2,042)   5,314 
Stock reserved for issuance to settle liabilities   (377)   2,455 
Debt features   (272)   - 
Changes in assets and liabilities          
Accounts receivable   2    5 
Prepaid expenses and other assets   59    (9)
Accounts payable   67    (24)
Accrued and other liabilities   54    (533)
Accrued restructuring   (380)   - 
Net cash used in operating activities   (495)   (1,065)
           
Investing activities:          
Change in restricted cash   380    - 
Net cash provided by investing activities   380    - 
           
Financing activities:          
Proceeds from sales of series C preferred shares and warrants, net   -    5,929 
Cash payments of notes payable   -    (250)
Insurance financing   (2)   (3)
Net cash provided by (used in) financing activities   (2)   5,676 
Net increase (decrease) in cash   (117)   4,611 
Cash and cash equivalents — Beginning of period   216    909 
Cash and cash equivalents — End of period  $99   $5,520 
Supplemental disclosure of cash flow information and non-cash financing activities:          
Cash paid for interest  $-   $83 
Reclassification of fair value liability for price adjustable warrants exercised  $-   $1,862 
Issuance of common stock to settle liabilities  $-   $3,474 
Debt conversion to common shares  $-   $1,479 
Deemed dividend to Series C convertible preferred stockholders  $-   $6,000 

 

See accompanying notes to the condensed consolidated financial statements.

 

5

  

MARINA BIOTECH, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended March 31, 2013 and 2014 (Unaudited)

 

Note 1 — Business, Liquidity and Summary of Significant Accounting Policies

 

Business

 

Marina Biotech, Inc. (collectively “Marina”, “the company”, “us” or “we”), in conjunction with our wholly-owned and financially consolidated subsidiaries, Cequent Pharmaceuticals, Inc. (“Cequent”), MDRNA Research, Inc. (“MDRNA”), and Atossa Healthcare, Inc. (“Atossa”), is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases. Since 2010, we have strategically acquired/in-licensed and further developed nucleic acid chemistry and delivery-related technologies to form an integrated drug discovery platform. We distinguish ourselves from others in the nucleic acid therapeutics area through this unique platform that enables the development of a variety of therapeutics targeting coding and non-coding RNA via multiple mechanisms of action such as RNA interference (“RNAi”), messenger RNA (“mRNA”) translational inhibition, exon skipping, miRNA (“miRNA”) replacement, miRNA inhibition, and steric blocking in order to modulate gene expression either up or down depending on the specific mechanism of action. Our goal is to dramatically improve the lives of the patients and families affected by orphan diseases through either our own efforts or those of our collaborators and licensees.

 

We are focusing our efforts and resources on the discovery and development of our own pipeline of nucleic acid-based compounds in order to commercialize drug therapies to treat orphan diseases. In addition, we will seek to establish collaborations and strategic partnerships with pharmaceutical and biotechnology companies to generate revenue through up-front, milestone and royalty payments related to our technology and/or the products that are developed using such technology.

 

Liquidity

 

The accompanying condensed consolidated financial statements have been prepared on the basis that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. At March 31, 2014, we had an accumulated deficit of approximately $340 million. To the extent that sufficient funding is available, we will in the future continue to incur losses as we continue our research and development (“R&D”) activities. In addition, we have had and will continue to have negative cash flows from operations. We have funded our losses primarily through the sale of common and preferred stock and warrants, revenue provided from our license agreements with other parties, and, to a lesser extent, equipment financing facilities and secured loans. At March 31, 2014, we had a working capital surplus of $3.0 million, which included $5.5 million in cash.

 

On February 24, 2014, certain debt holders exchanged secured promissory notes in the aggregate principal and interest amount of $1.5 million for 2.0 million shares of our common stock. In addition, on March 7, 2014, we entered into a Securities Purchase Agreement with certain investors pursuant to which we sold 1,200 shares of our Series C Convertible Preferred Stock (“Series C Preferred”), and warrants to purchase up to 6.0 million shares of our common stock at an exercise price of $0.75 per share, for an aggregate purchase price of $6.0 million. Each share of Series C Stock has a stated value of $5,000 per share and is convertible into shares of common stock at a conversion price of $0.75 per share. The Series C Stock is initially convertible into an aggregate of 8,000,000 shares of our common stock, subject to certain limitations and adjustments.

 

We believe that our current cash resources, which include the proceeds of the March 2014 offering of Series C Stock, will enable us to fund our intended operations through May 2015.

 

Basis of Preparation and Summary of Significant Accounting Policies

 

Basis of Preparation — The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles for complete financial statements. The accompanying unaudited financial information should be read in conjunction with the audited consolidated financial statements, including the notes thereto, as of and for the year ended December 31, 2013, included in our 2013 Annual Report on Form 10-K filed with the SEC. The information furnished in this report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of

 

6

  

operations and cash flows for each period presented. The results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results for the year ending December 31, 2014 or for any future period.

 

Use of Estimates — The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting periods. Estimates having relatively higher significance include revenue recognition, stock-based compensation, valuation of warrants, valuation and estimated lives of identifiable intangible assets, impairment of long-lived assets, valuation of features embedded within note agreements and amendments, and income taxes. Actual results could differ from those estimates.

 

Fair Value of Financial Instruments —We consider the fair value of cash, restricted cash, accounts receivable, accounts payable and accrued liabilities to not be materially different from their carrying value. These financial instruments have short-term maturities.

 

We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

 

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

 

Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

 

Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

 

Our cash and restricted cash are subject to fair value measurement and are valued determined by Level 1 inputs. We measure and report at fair value our accrued restructuring liability using discounted estimated cash flows. We measure the liability for committed stock issuances with a fixed share number using Level 1 inputs. We measure the liability for price adjustable warrants and certain features embedded in notes using the Black-Scholes-Merton valuation model, using Level 3 inputs. The following tables summarize our liabilities measured at fair value on a recurring basis as of December 31, 2013 and March 31, 2014:

 

       Level 1       Level 3 
   Balance at   Quoted prices in   Level 2   Significant 
   December 31,   active markets for   Significant other   unobservable 
   2013   identical assets   observable inputs   inputs 
Liabilities:                    
Fair value liability for price adjustable warrants  $5,226   $-   $-   $5,226 
Fair value liability for shares to be issued   1,019    1,019    -    - 
Total liabilities at fair value  $6,245   $1,019   $-   $5,226 

 

       Level 1       Level 3 
       Quoted prices in   Level 2   Significant 
   Balance at March   active markets for   Significant other   unobservable 
   31, 2014   identical assets   observable inputs   inputs 
Liabilities:                    
Fair value liability for price adjustable warrants  $14,606   $-   $-   $14,606 
Total liabilities at fair value  $14,606   $-   $-   $14,606 

  

7

  

The following presents activity of the fair value liability of price adjustable warrants determined by Level 3 inputs for the three-month period from December 31, 2013 to March 31, 2014:

 

       Weighted average as of each measurement date 
   Fair value                     
   liability for price               Contractual     
   adjustable warrants   Exercise   Stock       life   Risk free 
   (in thousands)   Price   Price   Volatility   (in years)   rate 
                         
Balance at December 31, 2013  $5,226   $0.28   $0.40    124%   4.08    1.30%
Cashless exercise of warrants   (1,862)   0.28    1.17    131    3.24    0.78 
Warrant issuance in connection with Series C   5,928    0.75    1.50    121    2.08    0.64 
Change in fair value included in statement of operations   5,314    -    -    -    -    - 
Balance at March 31, 2014  $14,606   $0.41   $0.89    125%   3.36    1.05%

 

Net Income (Loss) per Common Share — Basic net income (loss) per common share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share excludes the effect of common stock equivalents (stock options, unvested restricted stock, warrants, convertible debt-related shares) since such inclusion in the computation would be anti-dilutive and diluted income per common share includes these effects. The following number of shares have been excluded from diluted net income (loss) since such inclusion would be anti-dilutive:

 

   Three Months Ended March 31, 
   2013   2014 
Stock options outstanding   284,829    284,829 
Warrants   1,306,058    21,235,695 
Total   1,590,887    21,520,524 

 

The following is a reconciliation of diluted weighted average shares outstanding:

 

   Three Months Ended March 31, 
 (In thousands)  2013   2014 
Weighted average common shares outstanding   16,938    21,447 
Assumed conversion of net common shares issuable under warrants   2,078    - 
Assumed conversion of notes payable with conversion feature   5,270    - 
Weighted average common and common equivalent shares outstanding, diluted   24,286    21,447 

 

Recently Issued Accounting Standards - In May 2014, the Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers”, which provides guidance for revenue recognition. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosures. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016. We are currently in the process of evaluating the impact of adoption of this ASU on the financial statements.

 

In April 2014, the FASB issued ASU No. 2014-08, “Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity” which changes the criteria for determining which disposals can be presented as discontinued operations and modifies the related disclosure requirements. Under the new guidance, a disposal of a component of an entity or a group of components of an entity is required to be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results and is disposed of or classified as held for sale. The standard also introduces several new disclosures. The guidance applies prospectively to new disposals and new classifications of disposal groups as held for sale after the effective date. ASU 2014-08 is effective for annual and interim periods beginning after December 15, 2014, with early adoption permitted. We are currently in the process of evaluating the impact of adoption of this ASU on the financial statements.

 

8

 

Note 2 — Notes Payable

 

In February 2014, the holders of the secured promissory notes that we originally issued in February 2012, exchanged notes in the aggregate principal and interest amount of approximately $1.5 million for approximately 2.0 million shares of our common stock. The excess of the fair value of the common stock issued over the carrying value of the notes and accrued interest of $0.97 million was recorded as non-cash interest expense.

 

During the three months ended March 2013, we recorded interest and other expenses related to the notes of $0.06 million, with interest on the notes being $0.03 million and extinguishment accounting charges being $0.03 million. During the three months ended March 31, 2014 and prior to conversion of the notes payable to equity in March 2014, we recorded interest charges of $1.0 million, including $0.97 million related to the exchange of the notes and accrued interest for common stock, with the remainder being interest on the notes prior to exchange.

 

Note 3 — Stockholders’ Equity

 

Preferred Stock — Our board of directors has the authority, without action by the stockholders, to designate and issue up to 100,000 shares of preferred stock in one or more series and to designate the rights, preferences and privileges of each series, any or all of which may be greater than the rights of our common stock. We have designated 1,000 shares as Series B Preferred Stock (“Series B Preferred”) and 90,000 shares as Series A Junior Participating Preferred Stock (“Series A Preferred”). No shares of Series B Preferred or Series A Preferred are outstanding. In March 2014, we designated 1,200 shares of Series C Convertible Preferred Stock (“Series C Stock”).

 

In March 2014, we entered into a Securities Purchase Agreement with certain investors pursuant to which we sold 1,200 shares of Series C Stock, and price adjustable warrants to purchase up to 6.0 million shares of our common stock at an exercise price of $0.75 per share, for an aggregate purchase price of $6.0 million. Each share of Series C Stock has a stated value of $5,000 per share and is convertible into shares of common stock at a conversion price of $0.75 per share. The Series C Stock is initially convertible into an aggregate of 8,000,000 shares of our common stock, subject to certain limitations and adjustments, has no stated dividend rate, is not redeemable and has voting rights on an as-converted basis.

 

To account for the issuance of the Series C Stock and warrants, we first assessed the terms of the warrants and determined that, due to certain antidilution provisions, they should be recorded as derivative liabilities. We determined the fair value of the warrants on the issuance date and recorded a liability of $6.5 million. Since the fair value of the warrants exceed the total proceeds received of $6.0 million, we recorded a loss of $0.5 million upon issuance which is included in the change in fair value of price adjustable warrants in the statement of operations. The discount of $6.0 million on the Series C Stock resulting from the allocation of the entire proceeds to the warrant was accreted as a dividend on the Series C Stock through the earliest conversion date, which was immediately. The Series C Stock dividend of $6.0 million was recorded as both a debit and a credit to additional paid-in capital and as a deemed dividend on the Series C Stock in determining net loss applicable to common stock holders in the statement of operations. We incurred $0.07 million of stock issuance costs in conjunction with the Series C Stock which were netted against the proceeds.

 

Common Stock — Holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the holders of our common stock. Subject to the rights of the holders of any class of our capital stock having any preference or priority over our common stock, the holders of our common stock are entitled to receive dividends that are declared by our board of directors out of legally available funds. In the event of our liquidation, dissolution or winding-up, the holders of common stock are entitled to share ratably in our net assets remaining after payment of liabilities, subject to prior rights of preferred stock, if any, then outstanding. Our common stock has no preemptive rights, conversion rights, redemption rights or sinking fund provisions, and there are no dividends in arrears or default. All shares of our common stock have equal distribution, liquidation and voting rights, and have no preferences or exchange rights. Our common stock currently trades on the OTC Pink tier of the OTC Markets.

 

During the three months ended March 2014, we issued 0.09 million shares with a fair value of $0.10 million to a vendor under the terms of a 2012 compromise and release agreement.

 

In September 2012, as part of the lease termination agreement, we agreed to issue 1.5 million shares of our common stock to a landlord. The shares were issued in March 2014 with a fair value of $1.9 million.

 

9

  

As part of the asset purchase agreement that we entered into with Novosom in July 2010, we are obligated to pay Novosom 30% of any payments received by us for sub-licensed SMARTICLES® technology. The consideration is payable in a combination of cash (no more than 50% of total due) and common stock (between 50% and 100% of total due), at our discretion. For such consideration, in March 2014 we issued 0.96 million common shares with a fair value of $1.5 million in 2014.

 

During the three months ended March 2014, we issued 2.7 million shares of common stock with fair value of $1.0 million to employees and board members in settlement of amounts due under certain employment agreements and accrued board fees.

 

During the three months ended March 2014, we issued 0.08 million shares of common stock with a fair value of $0.03 million to directors and 0.1 million shares of common stock with a fair value of $0.03 million to scientific advisory board members for their services provided during this period.

 

During the three months ended March 2014, we issued 0.03 million shares of common stock with a fair value of $0.01 million to two consultants as compensation for services provided during this period.

 

Warrants — In January 2014, we issued warrants to purchase up to 0.10 million shares of our common stock to a consultant who is our interim chief financial officer. These warrants vest over two years, have a fixed strike price of $0.48, expire in January 2024 and have an immaterial fair value.

 

In March 2014, in conjunction with the issuance of Series C preferred (see above), we issued price adjustable warrants to purchase up to 6.0 million shares of our common stock at an exercise price of $0.75 per share, for an aggregate purchase price of $6.0 million.

 

During the three months ended March 31, 2014, we issued approximately 1.2 million shares upon net share exercise of warrants.

 

The following table summarizes warrant activity during the three months ended March 31, 2014:

  

   Warrant
Shares
   Weighted
Average
Exercise Price
 
Outstanding, December 31, 2013   17,017,601   $1.29 
Cashless exercises   (1,781,906)  0.38 
Issuance in connection with Series C convertible preferred shares   6,000,000   0.75 
Outstanding, March 31, 2014   21,235,695   $1.21 
Expiring in 2014   64,382      
Expiring in 2015   285,345      
Expiring in 2016   6,000,000      
Expiring thereafter   14,885,968      

 

Note 4 — Stock Incentive Plans

 

At March 31, 2014, options to purchase up to 0.28 million shares of our common stock were outstanding.

 

Stock-based Compensation. Certain option and share awards provide for accelerated vesting if there is a change in control as defined in the applicable plan and certain employment agreements. The following table summarizes stock-based compensation expense:

 

10

 

   Three months ended March 31, 
(In thousands)  2013   2014 
Research and development  $11   $10 
General and administrative   18    10 
Total  $29   $20 

 

 Stock Options — Stock option activity was as follows:

 

   Options Outstanding 
   2014 
   Shares   Weighted Average
Exercise Price
 
Outstanding on January 1   284,829   $39.46 
Outstanding on March 31   284,829   $39.46 
Exercisable as of March 31   256,708   $43.56 

 

The following table summarizes additional information on our stock options outstanding at March 31, 2014:

 

   Options Outstanding   Options Exercisable 
Range of Exercise
Prices
  Number
Outstanding
   Weighted-Average
Remaining
Contractual Life 
(Years)
   Weighted
Average
Exercise
Price
   Number
Exercisable
   Weighted
Average
Exercise
Price
 
$2.00 - $2.20   154,288    7.42   $2.02    126,167   $2.02 
$11.60 - $50.00   39,406    5.16    37.61    39,406    37.61 
$50.01 - $90.80   56,463    4.59    70.29    56,463    70.29 
$127.60 - $167.60   33,666    4.21    148.20    33,666    148.20 
$207.60 - $588.80   1,006    1.81    485.37    1,006    485.37 
Totals   284,829    6.86   $39.46    256,708   $43.56 
Exercisable   256,708    6.80                

 

No options were granted in the three months ended March 31, 2014.

 

At March 31, 2014, we had $0.04 million of total unrecognized compensation expense related to unvested stock options. We expect to recognize this cost over a weighted average period of eight months.

 

At March 31, 2014, the intrinsic value of options outstanding or exercisable was zero as there were no options outstanding with an exercise price less than the per share closing market price of our common stock at that date. No options were exercised during the periods ended March 31, 2013 and 2014.

 

Note 5 — Intellectual Property and Collaborative Agreements

 

Novosom — In July 2010, we entered into an agreement pursuant to which we acquired the intellectual property for Novosom’s SMARTICLES-based liposomal delivery system. During 2013, as a result of the payment received from Mirna for additional compounds, we opted to record a $0.15 million cash payable and reserve an additional 0.45 million shares for future issuance. All balances due Novosom, both cash and stock, were paid or issued in March 2014.

 

11

 

Note 6 — Commitments and Contingencies

 

 Standby Letter of Credit/Leases— In connection with the lease of our Bothell, Washington facility, we provided the landlord a $1.2 million stand-by letter of credit. The landlord drew $0.38 million in rent charges from the letter of credit in January and February 2013, before the credit facility was terminated in March 2013. At March 1, 2013, the Company had exited all facility leases, and the only remaining commitment was to issue 1.5 million common shares to the landlord, which were issued in March 2014.

 

Contingencies — We are subject to various legal proceedings and claims that arise in the ordinary course of business. Our management currently believes that resolution of such legal matters will not have a material adverse impact on our consolidated financial position, results of operations or cash flows.

 

Note 7 — Subsequent Events

 

Subsequent to March 31, 2014, we issued an aggregate of 0.03 million shares of our common stock with a fair value of $0.04 million to the four members of our Scientific Advisory Board and to one consultant.

 

12

 

ITEM 2 — MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Overview

 

Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statement made by us. These factors include, but are not limited to: (i) the ability of our company to obtain additional and substantial funding in the future; (ii) the ability of our company to attract and/or maintain research, development, commercialization and manufacturing partners; (iii) the ability of our company and/or a partner to successfully complete product research and development, including pre-clinical and clinical studies and commercialization; (iv) the ability of our company and/or a partner to obtain required governmental approvals, including product and patent approvals; and (v) the ability of our company and/or a partner to develop and commercialize products that can compete favorably with those of competitors. In addition, significant fluctuations in quarterly results may occur as a result of the timing of milestone payments, the recognition of revenue from milestone payments and other sources, and the timing of costs and expenses related to our research and development programs. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in our filings with the Securities and Exchange Commission, including those factors discussed under the captions “Risk Factors” and “Forward-Looking Statements” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, as may be supplemented or amended from time to time, which we urge investors to consider. We undertake no obligation to publicly release revisions in such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrences of unanticipated events or circumstances, except as otherwise required by securities and other applicable laws.

 

Background

 

We are a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases. Since 2010, we have strategically acquired/in-licensed and further developed nucleic acid chemistry and delivery-related technologies to form an integrated drug discovery platform. We distinguish ourselves from others in the nucleic acid therapeutics area through this unique platform that enables the development of a variety of therapeutics targeting coding and non-coding RNA via multiple mechanisms of action such as RNA interference (“RNAi”), messenger RNA (“mRNA”) translational inhibition, exon skipping, miRNA (“miRNA”) replacement, miRNA inhibition, and steric blocking in order to modulate gene expression either up or down depending on the specific mechanism of action. Our goal is to dramatically improve the lives of the patients and families affected by orphan diseases through either our own efforts or those of our collaborators and licensees.

 

We are focusing our efforts and resources on the discovery and development of our own pipeline of nucleic acid-based compounds in order to commercialize drug therapies to treat orphan diseases. In addition, we will seek to establish collaborations and strategic partnerships with pharmaceutical and biotechnology companies to generate revenue through up-front, milestone and royalty payments related to our technology and/or the products that are developed using such technology.

 

Cash Position and Liquidity

 

The accompanying condensed consolidated financial statements have been prepared on the basis that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. At March 31, 2014, we had an accumulated deficit of approximately $340 million. To the extent that sufficient funding is available, we will in the future continue to incur losses as we continue our research and development (“R&D”) activities. In addition, we have had and will continue to have negative cash flows from operations. We have funded our losses primarily through the sale of common and preferred stock and warrants, revenue provided from our license agreements with other parties, and, to a lesser extent, equipment financing facilities and secured loans. At March 31, 2014, we had a working capital surplus of $3.0 million, which included $5.5 million in cash.

 

On February 24, 2014, certain debt holders exchanged secured promissory notes in the aggregate principal and interest amount of $1.5 million for 2.0 million shares of our common stock. In addition, on March 7, 2014, we entered into a Securities Purchase Agreement with certain investors pursuant to which we sold 1,200 shares of Series C Stock, and warrants to purchase up to 6.0 million shares of our common stock at an exercise price of $0.75 per

 

13

  

share, for an aggregate purchase price of $6.0 million. Each share of Series C Stock has a stated value of $5,000 per share and is convertible into shares of common stock at a conversion price of $0.75 per share. The Series C Stock is initially convertible into an aggregate of 8,000,000 shares of our common stock, subject to certain limitations and adjustments, has no stated dividend rate, is not redeemable and has voting rights on an as-converted basis.

 

We believe that our current cash resources, which include the proceeds of the March 2014 offering of Series C Stock, will enable us to fund our intended operations through May 2015.

 

Cash flows

 

Our operating activities used cash of $1.1 million in the three months ended March 31, 2014, compared to $0.5 million in the three months ended March 31, 2013. In the three months ended March 31, 2014, cash used in operating activities related primarily to funding our net loss, adjusted for non-cash gains on the settlement of liabilities of $0.26 million. Adjustments for non-cash expenses totaling $8.8 million included charges related to beneficial conversion and debt extinguishment, interest expense, stock compensation, and the adjustment of warrants and stock to be issued to extinguish liabilities to reflect fair value. Changes in operating assets and liabilities used $0.6 million mostly from changes in accrued liabilities. In the three months ended March 31, 2013, cash used in operating activities related primarily to funding our net loss, adjusted for non-cash gains totaling $2.7 million related to changes in the fair value of the liability for price adjustable warrants, stock reserved to settle liabilities and embedded derivatives. Non-cash expenses totaling $1.0 million included the loss on debt extinguishment, interest expense and stock compensation. Changes in operating assets and liabilities used $0.2 million mostly from changes in the accrued restructuring.

 

We had no investing activities in the three months ended March 31, 2014; during the three months ended March 31, 2013, $0.4 million was drawn from our letter of credit associated with our lease termination.

 

Our financing activities provided $5.7 million in the three months ended March 31, 2014, compared to using $0.002 million in the three months ended March 31, 2013. Changes in cash from financing activities are primarily due to the sale of preferred stock and warrants to purchase common shares offset by cash we were required to pay the note-holders prior to conversion of the notes payable into equity.

 

Summary 

 

We believe that our current cash resources, which include the proceeds of the March 2014 offering of Series C Stock, will enable us to fund our intended operations through May 2015. The market value and the volatility of our stock price, as well as our historical financial situation and general market conditions, could make it difficult for us to complete a financing or collaboration transaction on favorable terms, or at all. Any financing we obtain may further, and substantially, dilute or otherwise impair the ownership interests of our current stockholders. If we fail to obtain significant additional capital in the future, we will be forced to further delay, reduce or eliminate some or all of our planned activities.

 

Consolidated Results of Operations

 

Comparison of Results of Operations for the three months ended March 31, 2014 to the three months ended March 31, 2013

 

Research and Development. R&D expense consists primarily of salaries and other personnel-related expenses, consulting and other outside services, and other costs. R&D expense declined 61% from $0.1 million in the three months ended March 31, 2013 to $0.05 million in the three months ended March 31, 2014, due to the following:

 

·Personnel-related expenses (compensation, benefits, travel related) decreased by 91% from $0.1 million in the first three months of 2013 to $0.01 million in the first three months of 2014 due to the resignation of our chief scientific officer at the end of 2013.

 

·Consulting fees increased 250% to $0.013 million in the three months ended March 31, 2014 from an immaterial amount in the first three months of 2013 as we resume development of our FAP product.

 

·The compensation for our scientific advisory board represented $0.02 million in the first three months of 2014 while there was no scientific advisory board compensation in the first three months of 2013.

 

In general, our strengthened financial position at March 31, 2014 has allowed us to subsequently increase R&D spending

 

14

  

as we resume development of our FAP product. We had yet to resume spending on R&D operations at March 31, 2014, resulting in an overall decline in R&D expenses for the three months ended March 31, 2014 compared to the same period in 2013.

 

General and administrative. General and administrative (“G&A”) expense consists primarily of salaries and other personnel-related expenses to support our R&D activities, stock-based compensation for G&A personnel and non-employee members of our Board, professional fees, such as accounting and legal, and corporate insurance costs. G&A costs increased 146% from $0.2 million in the three months ended March 31, 2013 to $0.5 million in the three months ended March 31, 2014 as a result of the following:

 

·Personnel-related expenses (compensation, benefits, travel related) increased 9% from $0.2 million in the three months ended March 31, 2013 to $0.22 million in the three months ended March 31, 2014 due primarily to the transition of our interim chief financial officer from management to the board of directors.

 

·Costs of legal and accounting fees, consulting, corporate insurance and other administrative costs decreased by 17% from $0.3 million in the three months ended March 31, 2013 to $0.25 million in the three months ended March 31, 2014 due to reduced expected fees related to audit and tax preparation and reduced legal fees.

 

·Also included in G&A in the first three months of 2013 was a credit of $0.3 million due to the reversal of a financing-related liability the payment of which was deemed remote.

 

In general, G&A expenses stayed relatively flat in the first three months of 2014 compared to the first three months of 2013 after adjusting for the one-time credit of $0.3 million in the first three months of 2013.

 

Interest & other expense. Interest and other expense increased from $0.06 million in the three months ended March 31, 2013 to $1.0 million in the three months ended March 31, 2014. This was mostly due to the 2014 non-cash interest expense related to the conversion of the notes payable into common stock.

 

Change in fair value liability for price adjustable securities. The fair value liability is revalued each balance sheet date utilizing Black-Scholes-Merton model computations, with the decrease or increase in fair value being reported in the statement of operations as other income or expense, respectively. The gain associated with this mark-to-fair value requirement was $2.0 million during the first three months of 2013, but stock price increases and the issuance terms of the Series C related warrants resulted in a $5.3 million loss during the first three months of 2014. The largest drivers of the change in the value of the liability are the number of price adjustable securities and the change in the stock price. We issued an additional 6 million price adjustable securities and our stock price went from $0.25 to $0.89 at March 31, 2013 and 2014, respectively. An increase in stock price increases the liability and increases our loss on the consolidated statements of operations.

 

Change in fair value liability for stock to be issued. During the first three months of 2014, we recognized a $2.5 million loss associated with the change in the value of share-based payments contractually obligated, but not yet issued. At March 31, 2013, we had contractually pledged 0.1 million shares to a vendor to partially settle an account payable, 0.5 million shares to Novosom to settle amounts owed under our license agreement, and 1.5 million shares to our landlord as part of our lease termination agreement. The increase in the market value of the shares due to stock price increases between December 31, 2013, and the date of issuance in March 2014, was recorded as a loss in the consolidated statement of operations.

 

Change in fair value of features embedded in notes payable. We recorded a gain of $0.3 million in the three months ended March 31, 2013 for the change in fair value of separately valued stand-alone features embedded in our notes payable. These features were revalued at each reporting period and the liability adjusted accordingly, with changes in the liability reflected as a gain or loss on the consolidated statements of operations. The change in the value of these features was tied to the stock price, such that price declines within the reporting period reduced the fair value of the liabilities and was recorded as a gain on the consolidated statements of operations. The gain was offset when substantially equivalent losses were incurred on debt extinguishment, as discussed below. The notes and all such features were extinguished in March 2014.

 

Loss on Debt Extinguishment. Due to the requirements under debt extinguishment accounting, the fair value of existing debt is extinguished on the date of certain note amendments. Any concurrent warrant issuances and the fair value of any embedded features within the notes are fully expensed as a gain or loss on extinguishment, then the note terms and features are revalued and rebooked on the balance sheet. In the three months ended March 31, 2013, a $0.9 million loss was recorded due to extinguishment of the debt related to the February 2013 amendment.

 

15

  

Gain on settled liabilities. During the three months ended March 31, 2014, we recorded a $0.26 million gain due to the negotiated settlement of liabilities accrued for our executive officers. The remaining liabilities to those officers of $1.0 million were paid through the issuance of 2.8 million common shares with a fair value of $1.0 million.

 

Off-Balance Sheet Arrangements

 

As of March 31, 2014, we did not have any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of SEC Regulation S-K.

 

ITEM 3 — QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

ITEM 4 — CONTROLS AND PROCEDURES

 

(a) Disclosure Controls and Procedures. As of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our senior management, including our principal executive officer and our principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Management identified material weaknesses in internal control over financial reporting as described under the heading “Management Report on Internal Control” contained in Item 9A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (the “2013 Form 10-K”), which have not been remediated, and therefore our principal executive officer and our principal financial officer concluded that, as of March 31, 2014, our disclosure controls and procedures were not effective.

 

(b) Internal Control Over Financial Reporting. Management has reported to the Board of Directors and the Audit Committee thereof material weaknesses described under the heading “Management Report on Internal Control” contained in Item 9A of the 2013 Form 10-K. The material weaknesses discussed therein have not been remediated. There have been no changes in our internal control over financial reporting or in other factors during the fiscal quarter ended March 31, 2014 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. However, our current and historical financial condition, loss of substantially all personnel, and cessation of day-to-day operations, particularly during the period covered by the 2013 Form 10-K and during subsequent reporting periods, including the period covered by this report, have placed substantial pressure on our system of internal control over financial reporting. With the availability of funds, we intend to put in place a stronger internal control process by hiring individuals or consultants to establish increased oversight on our financial reporting.

 

16

  

PART II — OTHER INFORMATION

  

ITEM 2 — UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

During the fiscal quarter ended March 31, 2014, we issued an aggregate of 118,181 shares of our common stock to the four members of our Scientific Advisory Board and to two consultants. The shares were issued in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act.

 

ITEM 6 — EXHIBITS

 

The exhibits required by this item are set forth in the Exhibit Index attached hereto.

 

17

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, duly authorized, in Cambridge, Massachusetts, on August 19, 2014.

 

  MARINA BIOTECH, INC.
     
  By: /s/ J. Michael French
    J. Michael French
    President and Chief Executive Officer
    (Principal Executive Officer and
    Principal Financial Officer)

 

18

  

EXHIBIT INDEX

 

Exhibit 
No. 
  Description   
     
31.1   Certification of our Principal Executive Officer and Principal Financial Officer pursuant to Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934, as amended. (1)
     
32.1   Certification of our Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (2)
     
101.INS   XBRL Instance Document (2)
     
101.SCH   XBRL Taxonomy Extension Schema Document (2)
     
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document (2)
     
101.DEF   XBRL Taxonomy Extension Definitions Linkbase Document (2)
     
101.LAB   XBRL Taxonomy Extension Label Linkbase Document (2)
     
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document (2)

 

 

  (1) Filed Herewith.
  (2) Furnished Herewith.

 

19